Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05385887
Other study ID # NL75540.018.20
Secondary ID 2020-004449-35
Status Recruiting
Phase N/A
First received
Last updated
Start date December 23, 2021
Est. completion date August 1, 2025

Study information

Verified date November 2023
Source Proctos Kliniek
Contact Ingrid M Han-Geurts, Dr.
Phone 030 225 0260
Email i.han@proctoskliniek.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale: Perianal fistula is a burdening disease with an annual prevalence of 2/100.000 in the Dutch population. More than 90% of crypto-glandular fistulas originate from anorectal abscess. Despite adequate drainage of anorectal abscess up to 83% recurs or results in an anal fistula, the majority developing within 12 months. Up till now it is not common practice to routinely administer prophylactic antibiotics to prevent anal fistula development.\ Objective: The objective of this trial is to establish if adding antibiotic treatment to surgical drainage of perianal abscess results in less perianal fistulas. Study design: The study concerns a double-blind, placebo-controlled, randomized, multicenter trial with treatment of perianal abscess by surgical drainage alone or combined with antibiotic treatment. Patients will be accrued by all participating clinics. The design involves allocation of all appropriate consecutive patients with a primary occurrence of perianal abscess to surgical drainage followed by either antibiotics or placebo. Data will be analyzed on 'intention to treat' basis in case patients are not subjected to the randomized treatment modality. Study population: Men and women of 18 years and older who present for the first time with a perianal abscess. Intervention (if applicable): The antibiotic group receives 7 days of oral metronidazole (500 mg every eight hours) and ciprofloxacin (500 mg every twelve hours) in addition to surgical drainage. The other group receives surgical drainage and postoperatively identical placebo tablets. Main study parameters/endpoints: Primary outcome measure is development of a perianal fistula. Secondary outcome measures are quality of life at 12 months measured with the EQ-5D-5L with Dutch rating. Further: in-hospital direct and indirect costs and out-of hospital postoperative costs, need of repeated drainage, patient related outcome (PRO) and clinical outcome measures. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: For this study, patients are asked to take part in a study comparing the addition of antibiotic treatment to surgical drainage of perianal abscess. Patients will not be burdened by extra hospital visits. At baseline participants will complete PRO questionnaires. Also at 1 week and 3, 6 and 12 months participants will fulfill the PRO questionnaires. These will be send to them by email and will take approximately 10 minutes each time.


Recruitment information / eligibility

Status Recruiting
Enrollment 298
Est. completion date August 1, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women aged 18 years or older - Eligible for e-mail questionnaires - Sufficient understanding of the Dutch written language (reading and writing) - Obtained written informed consent Exclusion Criteria: - A coexistent anorectal fistula - Secondary or recurrent anorectal abscess - Presence of an internal fistula opening - Any additional surgical procedure performed during the same session - Previous (peri)anal surgery - Inflammatory bowel disease - History of radiation of the pelvic area - Anorectal malignancy - Immunodeficiency - Kidney failure (eGFR <30ml/min) - Valvular heart disease - Pregnancy or lactation - Postoperative antibiotic prophylaxis indicated for another reason - Immunosuppressive medication at the time of surgery - Allergy to metronidazole or ciprofloxacin - Not able or trouble with swallowing pills - Concomitant use of: - Tizanidine, theophylline, clozapine, olanzapine, pirfenidone, carbamazepine, agomelatine (these are all CYP1A2 substrates, ciprofloxacin is an inhibitor) - Amiodarone, erythromycin, sotalol, azithromycin, citalopram, escitalopram, flecainide, fluconazole, haloperidol >5mg/day, methadone, ondansetron (concerning prolonged QT interval in combination with ciprofloxacin) - Lithium (can cause toxic levels with metronidazole) - Lopinavir/ritonavir, ritonavir capsules, temsirolimus, disulfiram (antabuse), mebendazole (can cause serious side effects, confusion and psychosis in combination with metronidazole) - Corticosteroids (in combination with ciprofloxacin higher risk of tendinitis and tendon rupture).

Study Design


Intervention

Drug:
Ciprofloxacin 500 mg
One tablet of 500mg Ciprifloxacine, twice a day
Metronidazole 500 mg
One tablet of 500mg Metronidazole, three times a day
Placebo
Placebo tablets

Locations

Country Name City State
Netherlands Flevoziekenhuis Almere
Netherlands OLVG Amsterdam North-Holland
Netherlands University Medical Center location AMC Amsterdam
Netherlands Rode Kruis ziekenhuis Beverwijk Noord-Holland
Netherlands Proctos kliniek Bilthoven Utrecht
Netherlands Amphia hospital Breda North-Brabant
Netherlands IJsselland ziekenhuis Capelle Aan Den IJssel
Netherlands Albert Schweitzer ziekenhuis Dordrecht Zuid-Holland
Netherlands Dijklander hospital Hoorn North-Holland
Netherlands Elisabeth-TweeSteden ziekenhuis Tilburg Noord-Brabant
Netherlands Diakonessenhuis Utrecht

Sponsors (2)

Lead Sponsor Collaborator
dr. IJM Han-Geurts Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Perianal fistula at 1 year follow up A perianal fistula is diagnosed based on findings from physical examination or by a telephone call after 12 months were the doctor asks for symptoms as serosanguinous discharge and pain. An external opening with or without serosanguilent discharge is considered a fistula. In case of doubt an endoanal ultrasonography or MRI is performed.
So: yes/no fistula (dichotomous parameter)
1 year
Secondary Quality of life at 12 months measured with the EQ-5D-5L with Dutch rating. The EQ-5D-5L is a generic Health Related Quality of Life (HRQoL) measure, which is broadly used in economic evaluation. The instrument examines a patient's HRQoL on the day of the interview. It consists of the EQ-5D-5L descriptive system and the EQ-Visual Analogue Scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses to the 5 items result in a patient's health state that can be transformed into an index score representing health-related quality of life, ranging between 0 (death) and 1 (full health). These index scores are combined with length of life to calculate the QALY. The EQ-VAS records the patient's self-rated health with endpoints labelled 'the best health you can imagine' at the top and 'the worst health you can imagine' at the bottom. 1 year
Secondary In-hospital direct and indirect costs and out-of hospital posteroperative costs In-hospital direct and indirect costs (measured with iPCQ and iMCQ) and out-of hospital postoperative costs. 1 year
Secondary Need of repeated drainage 1 year
Secondary PROMs Patient related outcome (PRO) are complaint reduction assessed by a proctology specific validated patient-related outcome measure, the proctoPROM(14). This was recently developed and validated at Proctos Clinic. At baseline participants will complete PRO questionnaires. Also at 1 week and 3, 6 and 12 months participants will fulfill the PRO questionnaires. These will be send to them by email with access to a web tool (Castor). If the patient does not have an email account, the questionnaires will be send the patients' home address, accompanied by a return envelope provided with postage stamps and the address of the hospital. 1 year
Secondary Day of discharge from hospital Day of discharge from hospital; 1 year
Secondary Postoperative complications Complications (postoperative bleeding, urinary retention requiring catheterisation, emergency reoperation, anal stenosis and fecal incontinence) including death and cause of death within 30 days will be reported using the Clavien-Dindo classification of surgical complications(15). 1 year
Secondary Recurrent abscess (Recurrent) abscess within one year. Yes/no (dichotomous) 1 year
Secondary Duration of absence from work Duration of absence from work. Amound of days is recorded (continuous scale) 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03913572 - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Terminated NCT01623453 - Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211) N/A
Completed NCT06441526 - Surgical Closure vs Anti-TNF in the Treatment of Perianal Fistulas in Crohn's Disease (PISA-II): a Comprehensive Cohort Design Phase 3
Recruiting NCT04847739 - Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II) Phase 2
Completed NCT06314945 - Diagnostic Value of Recto-perineal Ultrasound in Perianal Fistula
Completed NCT03763981 - Comparison of Prolene Thread Seton Vs Silk Thread Seton for the Treatment of Perianal Fistula N/A
Not yet recruiting NCT05626023 - A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease Phase 1/Phase 2
Completed NCT01021774 - Anal Fistula Treatment Outcome - Collagen Plug Versus Advancement Flap Surgery N/A
Recruiting NCT04519671 - Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease Phase 1/Phase 2
Active, not recruiting NCT04549311 - Perianal Abscess Recurrence and Fistula Formation: Antibiotics Following Incision and Drainage Trial Phase 3
Completed NCT03555773 - Micro-fragmented Adipose Tissue and Complex Crohns' Anal Fistulas N/A
Recruiting NCT03707769 - TIPS Microspheres for Perianal Fistula N/A
Completed NCT03803917 - Adipose Tissue in Crohn´s Disease Fistulas N/A
Recruiting NCT03322488 - Fistulodesis Pilot Study for Closure of Perianal Fistulae N/A
Withdrawn NCT03014219 - Phase 1 Crohn's Pediatric Sub-study of MSC AFP Phase 1
Completed NCT03209700 - Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas Phase 1
Completed NCT03981939 - Perianal Fistula (PAF) Validation and Burden of Illness Study
Recruiting NCT05721794 - Comparative Accuracy of Transperineal Ultrasound (TPUS) Versus Magnetic Resonance Imaging (MRI) for the Assessment of Perianal Fistulae in Patients With Crohn's Disease (CD): a Prospective Observational Longitudinal Cohort Study
Enrolling by invitation NCT03861689 - Tight Control Management in Perianal Crohn's Disease N/A
Not yet recruiting NCT05709717 - Regenerative Therapy With Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cells and Platelet-rich Plasma to Treat Complex Perianal Diseases